ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	ClinicalTrials.gov
Last refreshed on:	12 December 2020
Main ID:	NCT00532571
Date of registration:	18/09/2007
Prospective Registration:	No
Primary sponsor:	Lahey Clinic
Public title:	Effects of Coenzyme Q10 in PSP and CBD
Scientific title:	Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study
Date of first enrolment:	January 2004
Target sample size:
Recruitment status:	Completed
URL:	https://clinicaltrials.gov/show/NCT00532571
Study type:	Interventional
Study design:	Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double.
Phase:	Phase 2/Phase 3

Countries of recruitment
United States

Contacts

Name:	Diana Apetauerova, MD
Address:
Telephone:
Email:
Affiliation:	Lahey Clinic

Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were
diagnosed within the past 5 years

- Age > 40

- Subjects receiving anticholinergics, amantadine, dopamine agonists,
carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days
prior to baseline visit.

- Patients agreeable to participate in the study.

Exclusion Criteria:

- Prior or concurrent therapy with anticholinergics, amantadine,a dopamine
agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.

- Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.

- History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue
transplant.

- Previous use of coenzyme Q10 within 60 days of the baseline visit.

Age minimum: 40 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Progressive Supranuclear Palsy

Neurological Disorders

Intervention(s)

Drug: CoQ10

Primary Outcome(s)

Secondary Outcome(s)

Secondary ID(s)

CoQ10 with PSP/CBD

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Ethics review

Results

Results available:
Date Posted:
Date Completed:
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.